FDA device-report analysis flags higher serious injury and death rates for histotripsy vs thermal ablation

Retrospective · Radiology · 2026-11-18. Number 2 in the UrologyWatch Top 5 for November 18, 2026.

Analysis of FDA MAUDE reports found higher rates of serious injury (86% vs 20%) and death (14% vs 2%) among histotripsy adverse event reports compared with microwave/radiofrequency ablation over comparable 24-month postmarket periods.

Why it matters: Raises safety questions about early postmarket histotripsy use that warrant prospective evaluation; MAUDE reporting is passive and not denominator-adjusted.

Limitation: Passive adverse event database without true denominators; comparisons use modeled procedure volumes as proxies.

Source: Radiology · PubMed 43043182 · DOI 10.1148/radiol.261687

The full November 18, 2026 edition · Today's urology news

Loading today's edition…